Urokinase is a white powder.
This product is mainly used for thrombolytic treatment of thromboembolic
diseases. These included acute extensive pulmonary embolism, coronary artery
embolization and myocardial infarction within 6-12 hours of chest pain, acute
stage cerebral vascular embolization with symptoms shorter than 3-6 hours,
retinal artery embolization, and other severe peripheral arterial embolization
of ilio-femoral vein thrombosis. It is also used to prevent thrombus formation
after artificial heart flap operation, and to keep the vascular intubation and
the thoracic cavity and pericardial cavity drainage tube unobtrusive. The
therapeutic effect of thrombolytic therapy should be maintained by subsequent
heparin anticoagulation.
pharmacological action
The goods can direct effects on endogenous fibrinolysis system into a
fibrinolytic enzyme catalytic cracking fibrinolytic enzyme, which can not only
degradation of fibrin clot, also can degrade fibrinogen in blood, and clotting
factor Ⅴ and blood coagulation factor Ⅷ etc, so as to play a role of
thrombolysis. The product has quick and good effect on the newly formed
thrombus. The product can also improve the activity of vascular ADP enzyme,
inhibit adp-induced platelet aggregation, and prevent thrombosis. After
intravenous infusion, the fibrinolytic enzyme activity in the patients increased
significantly. Several hours after discontinuation, fibrinolytic activity
returned to its original level, but the reduction in plasma fibrin or fibrinogen
levels and the increase in their degradation products lasted for 12-24 hours.
The results showed that the thrombolytic effect was significantly correlated
with the dosage and time window of administration. The toxicity was very low,
and the lethal dose of intravenous injection of half of the mice was more than 1
million ius/kg body weight. There was no obvious antigenicity, teratogenicity,
carcinogenicity or mutagenicity. There are few reports of anaphylaxis in
clinical application. However, as the product increases the activity of
fibrinolytic enzyme and reduces the unbound plasminogen and fibrinogen binding
to fibrin in blood circulation, serious bleeding risk may occur.